Related Experiment Video
Updated: May 28, 2026
09:09
Isolation and In Vitro Culture of Murine and Human Alveolar Macrophages
Published on: April 20, 2018
Human neutrophil peptide in lung chronic allograft dysfunction
Cavan Reilly1, Tereza Cervenka, Marshall I Hertz
1Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Summary
Human neutrophil peptide (HNP) is a promising biomarker for predicting bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Elevated HNP levels early on indicate a higher risk of developing BOS.
Area of Science:
- Pulmonary Medicine
- Transplant Immunology
Background:
- Bronchiolitis obliterans syndrome (BOS) is a major complication following lung transplantation.
- Human neutrophil peptides (HNPs) were previously identified as potential biomarkers for BOS.
- A case-control study suggested HNP's role in BOS development.
Purpose of the Study:
- To prospectively validate human neutrophil peptide (HNP) as a reliable biomarker for BOS.
- To assess the predictive value of HNP levels for BOS development in lung transplant recipients.
Main Methods:
- Human neutrophil peptide (HNP) levels were measured using ELISA.
- Bronchoalveolar lavage (BAL) fluid was collected from lung transplant recipients.
- HNP was assessed in relation to pulmonary function and BOS development.
Main Results:
- Early HNP measurements post-transplant predicted the development of BOS ≥2 (p=0.0419).
- HNP levels remained elevated in patients who developed BOS.
- Confounding factors did not significantly alter BOS-free survival time.
Conclusions:
- Elevated HNP levels are an early indicator of BOS development.
- HNP is a persistent biomarker in lung transplant recipients who develop BOS.
- HNP shows potential for early diagnosis and monitoring of BOS.
